Eli Lilly

Omeros adds two new vice presidents to management team

Friday, October 19, 2012 02:21 PM

Omeros, a Seattle, Wash.-based clinical-stage biopharmaceutical company targeting inflammation, coagulopathies and disorders of the central nervous system, has appointed two new vice presidents: Cathy Melfi, Ph.D. as vice president, regulatory affairs and quality systems, and Albert Yu, M.D., as vice president, clinical development.

More... »

Clinical research sites honor Eli Lilly, Medpace with Eagle Awards

Monday, October 15, 2012 11:57 AM

The 2012 Eagle Awards, presented to the top sponsor and top CRO as voted by clinical research sites, honored Eli Lilly and Medpace on Saturday, Oct. 13, at the annual Site Solutions Summit.

More... »

Investigational drugs chosen for major Alzheimer's prevention trial

Thursday, October 11, 2012 07:00 AM

Scientists have selected the first investigational drugs for a worldwide Alzheimer's disease prevention trial. The pioneering study, expected to start by early 2013, initially will test three promising drugs—gantenerumab, solanezumab and an unnamed BACE inhibitor—each designed to target Alzheimer's in different ways.

More... »

10 pharmas form nonprofit TransCelerate to accelerate R&D of new medicines

Wednesday, September 19, 2012 02:46 PM

Ten biopharmaceutical companies have formed a non-profit organization, TransCelerate BioPharma, to accelerate the development of new medicines. Participants include Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi.

More... »

Prevention trial studies population 100% genetically predisposed to early-onset Alzheimer’s

Monday, August 6, 2012 07:00 AM

For the first time ever, an experimental drug is being tested to determine whether it can prevent Alzheimer’s disease in a population that has a 100% genetic predisposition for early onset of the disease. The study, to start next year, will be one of only a few being conducted to test prevention treatments for a genetically predestined disease.

More... »

Lilly pomaglumetad methionil study falls short of primary endpoint

Thursday, July 12, 2012 04:35 PM

Eli Lilly reported negative clinical trial results from study H8Y-MC-HBBM (HBBM) investigating pomaglumetad methionil, also known as mGlu2/3, for the treatment of acute exacerbation of schizophrenia.

More... »

Lilly expands partnership with Novast for branded generics

Thursday, June 14, 2012 02:53 PM

In support of its commitment to maximize growth opportunities in China, Eli Lilly has increased its network of manufacturing capabilities in this key emerging market country through an expanded collaboration with Novast Laboratories.

More... »

Lilly launches trial-finding mobile app for cancer patients

Friday, June 1, 2012 03:49 PM

Eli Lilly’s cancer division, Lilly Oncology, has launched a searchable clinical trial mobile application for oncology healthcare professionals.

More... »

Teralys Capital, Lilly invest in new $150 million fund for life sciences

Wednesday, May 30, 2012 10:36 AM

Teralys Capital has invested $65 million, along with other amounts from Eli Lilly and other partners, in TVM Life Science Ventures VII, which closed on an initial size of $150 million.

More... »

Lilly reports positive data in phase II diabetes study of dulaglutide

Friday, May 25, 2012 01:16 PM

Eli Lilly’s investigational drug dulaglutide, a long-acting glucagon-like peptide 1 (GLP-1) analog being studied as a once-weekly treatment for type 2 diabetes, met its primary endpoint of non-inferiority for mean 24-hour systolic blood pressure (SBP, or pressure while the heart contracts) after 16 weeks.

More... »